{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T15:15:27Z","timestamp":1697296527682},"reference-count":20,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2003,11,20]],"date-time":"2003-11-20T00:00:00Z","timestamp":1069286400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2004,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We previously showed that a new vitamin D analog, 1\u03b1(OH)D5 (D5), induced differentiation and inhibited the growth of breast cancer cells. In this report, we examined whether D5 specifically delivered to breast cancer cells could have any therapeutic effect. D5 was linked to Her\u20102 antibody using sulfosuccinimidyl 6\u20104 azido nitrophenylamido hexanode (SANPAH) as a linker. The Her\u20102 antibody selected in our study had no significant effect on the <jats:italic>in vitro<\/jats:italic> or <jats:italic>in vivo<\/jats:italic> growth of breast cancer cells; however, it had cell\u2010differentiating action. <jats:italic>In vitro<\/jats:italic>, D5\u2010Her\u20102 antibody conjugate (IMC) showed the ability to specifically bind to Her\u20102\u2010expressing cells, to compete with Her\u20102 antibody for surface receptor and to cause internalization. IMC (equivalent to 5 \u03bcg Her\u20102 antibody given intraperitoneally once weekly for 6 weeks) significantly inhibited the growth of BT\u2010474 cells transplanted into athymic mice. The <jats:italic>in vivo<\/jats:italic> growth\u2010inhibitory effect of IMC treatment was similar to that observed in animals receiving D5 continuously as a dietary supplement. These results show that the targeted delivery of D5 by immunoconjugation to cell surface receptor antibodies may be of potential therapeutic value for the treatment of Her\u20102 positive breast cancer. \u00a9 2003 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ijc.11590","type":"journal-article","created":{"date-parts":[[2004,1,2]],"date-time":"2004-01-02T23:00:41Z","timestamp":1073084441000},"page":"922-929","source":"Crossref","is-referenced-by-count":4,"title":["Effect of vitamin D analog (1\u03b1 hydroxy D5) immunoconjugated to Her\u20102 antibody on breast cancer"],"prefix":"10.1002","volume":"108","author":[{"given":"Vasil","family":"Punj","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jewell M.","family":"Graves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajeshwari R.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,1,2]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"1","article-title":"Current management of metastatic breast cancer","volume":"26","author":"Perez E","year":"1999","journal-title":"Semin Oncol"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.18.3230"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.3798106"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02826212"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00125480-200007030-00005"},{"key":"e_1_2_5_7_2","first-page":"905","article-title":"Role of Her\u20102\/neu oncogene amplification in determination of outcome of patients with cancer","volume":"113","author":"Sethi S","year":"2000","journal-title":"Am J Clin Pathol"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199405053301802"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006394317282"},{"key":"e_1_2_5_10_2","first-page":"2534","article-title":"Antitumor effect of 22\u2010oxa\u2010calcitrol, a noncalcemic analog of calcitrol in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen","volume":"53","author":"Abe\u2010Hoshimoto J","year":"1993","journal-title":"Cancer Res"},{"key":"e_1_2_5_11_2","first-page":"5711","article-title":"Inhibition of breast cancer cell growth by combined treatment with vitamin D3 analogs and tamoxifen","volume":"54","author":"Vink\u2010van Wijnggarden T","year":"1994","journal-title":"Cancer Res"},{"key":"e_1_2_5_12_2","first-page":"519","article-title":"Combination therapy of a vitamin D3 analog and all trans retinoic acid: effect on human breast cancer in nude mice","volume":"19","author":"Koshizuka K","year":"1999","journal-title":"Anticancer Res"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3835(95)03765-O"},{"key":"e_1_2_5_14_2","first-page":"1689","article-title":"20\u2010cyclopropyl\u2010cholecaliferol vitamin D3 analogs: a unique inhibitor of proliferation of human prostate, breast, and myeloma cell lines","volume":"19","author":"Koike M","year":"1999","journal-title":"Anticancer Res"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006123819675"},{"key":"e_1_2_5_16_2","first-page":"65","article-title":"Differentiation of human breast carcinoma cell line by a novel vitamin D analog: 1alpha\u2010hydroxyvitamin D5","volume":"16","author":"Mehta RR","year":"2000","journal-title":"Int J Oncol"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(00)00016-2"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1210\/edrv-3-4-331"},{"key":"e_1_2_5_19_2","first-page":"413","article-title":"The relationship between the vitamin D system and cancer","volume":"206","author":"Deluca HF","year":"1986","journal-title":"Adv Exp Biol Med"},{"key":"e_1_2_5_20_2","first-page":"933","article-title":"Preclinical toxicity of 1alpha\u2010hydroxyvitamin D5 in rats and dogs","volume":"42","author":"Johnson WD","year":"2001","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_5_21_2","first-page":"497","article-title":"Mutation of the human neu protein facilitates down modulation by monoclonal antibodies","volume":"5","author":"Van Leeuwen F","year":"1990","journal-title":"Oncogene"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.11590","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.11590","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T14:32:03Z","timestamp":1697293923000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.11590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1,2]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["10.1002\/ijc.11590"],"URL":"https:\/\/doi.org\/10.1002\/ijc.11590","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,1,2]]}}}